Erdem Aktaş

Erdem Aktaş

Auto-generated profile, based on publicly available information

Erdem Aktaş

Department of Orthopedics and Traumatology, TOBB ETU Faculty of Medicine, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2016 in Journal of Orthopaedic Research
Verified
Journal Article
Open access
PDF file
EAErdem Aktas
Erdem Aktas
CCConnie S. Chamberlain
Connie S. Chamberlain
ESErin E. Saether
Erin E. Saether
SDSarah E. Duenwald‐Kuehl
Sarah E. Duenwald‐Kuehl
JKJaclyn Kondratko‐Mittnacht
Jaclyn Kondratko‐Mittnacht
RVRay Vanderby
Ray Vanderby
Tendon healing is a complex coordinated series of events resulting in protracted recovery, limited regeneration, and scar formation. Mesenchymal stem cell (MSC) therapy has shown promise as a new technology to enhance soft tissue and bone healing. A challenge with MSC therapy involves the ability to consistently control the inflammatory response and subsequent healing. Previous studies suggest that preconditioning MSCs with inflammatory cytokines, such as IFN‐γ, TNF‐α, and IL‐1β may accelerate cutaneous wound closure. The objective of this study was to therefore elucidate these effects in tendon. That is, the in vivo healing effects of TNF‐α primed MSCs were studied using a rat Achilles segmental defect model. Rat Achilles tendons were subjected to a unilateral 3 mm segmental defect and repaired with either a PLG scaffold alone, MSC‐seeded PLG scaffold, or TNF‐α‐primed MSC‐seeded PLG scaffold. Achilles tendons were analyzed at 2 and 4 weeks post‐injury. In vivo, MSCs, regardless of priming, increased IL‐10 production and reduced the inflammatory factor, IL‐1α. Primed MSCs reduced IL‐12 production and the number of M1 macrophages, as well as increased the percent of M2 macrophages, and synthesis of the anti‐inflammatory factor IL‐4. Primed MSC treatment also increased the concentration of type I procollagen in the healing tissue and increased failure stress of the tendon 4 weeks post‐injury. Taken together delivery of TNF‐α primed MSCs via 3D PLG scaffold modulated macrophage polarization and cytokine production to further accentuate the more regenerative MSC‐induced healing response. © 2016 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 35:269–280, 2017.

6 December 2016 in Journal of Plastic Surgery and Hand Surgery
Verified
Journal Article
Closed access
HUHakan Uzun
Hakan Uzun
OBOzan Bitik
Ozan Bitik
ÖUÖznur Uzun
Öznur Uzun
UEUmut Sinan Ersoy
Umut Sinan Ersoy
EAErdem Aktaş
Erdem Aktaş
Background: Platelet-rich plasma therapy has the potential to promote peripheral nerve regeneration through the autologous supply of growth factors. Therefore, this study aimed to compare the effects of platelet-rich plasma injections with the effects of corticosteroid injections in the treatment of carpal tunnel syndrome. Methods: In total, 40 patients with mild carpal tunnel syndrome were equally divided into two groups. Nerve conduction studies were carried out, and the Boston Carpal Tunnel Questionnaire was administered to both groups before treatment. One group of patients received platelet-rich plasma injections, and the patients in the other group received corticosteroid injections into the carpal tunnel. The patients were followed for 6 months. After 3 and 6 months, the nerve conduction studies and the Boston Carpal Tunnel Questionnaire were repeated. Results: Although distal motor latencies did not change in either of the groups during the follow-up period, improvements in sensory nerve conduction were recorded after 3 months in both groups. However, there was no significant difference between the groups in the nerve conduction studies. In the Boston Carpal Tunnel Questionnaire, both the symptom severity score and the functional capacity score of the platelet-rich plasma group were significantly better than those of the corticosteroid group after 3 months, although there were no significant differences after 6 months. Conclusions: Platelet-rich plasma injections may be considered for the temporary symptomatic relief of mild carpal tunnel syndrome.

24 August 2011 in Journal of Orthopaedics and Traumatology
Verified
Journal Article
Open access
PDF file
EAErdem Aktas
Erdem Aktas
ESErtugrul Sener
Ertugrul Sener
PGPınar Uyar Gocun
Pınar Uyar Gocun
Background We investigated the anti-inflammatory and immunomodulatory effect of simvastatin on articular cartilage via the inhibition of matrix metalloproteinase-3 (MMP-3), a matrix-degrading enzyme, in a mechanically induced experimental osteoarthritis (OA) animal model. Materials and methods Twenty-seven albino Wistar rats were divided in three groups of equal number. Unphysiologic loading of articular cartilage was simulated by transecting anterior cruciate ligaments of the right knees of 18 rats consisting of groups 1 and 2. Nine animals in group 2 received orally administered simvastatin 20 mg/kg per day by gavage for 8 weeks. Animals in group 3 were sham operated. All animals were sacrificed at postoperative 8 weeks. Effects of simvastatin on disease progression was evaluated by documenting OA changes in cartilage specimens using Osteoarthritis Research Society International (OARSI) OA cartilage histopathology assessment system scores combined with the percentage of MMP-3 expression in chondrocytes. Results Simvastatin treatment significantly down-regulated the percentage of MMP-3 expression in chondrocytes as assessed by immunohistochemistry methods. Suppression of this matrix-degrading enzyme by simvastatin also reduced OARSI scores, suggesting the potential for statins against OA progression. Conclusions Following knee trauma, OA initiates at the molecular level in a short period of time. Irreversible structural changes in cartilage that require demanding treatment strategies led us to focus on effective measures to prevent OA. Statins have immunomodulatory and anti-inflammatory properties independent from their serum-cholesterol-lowering effects. One of these widely used drugs, simvastatin, showed beneficial effects on OA progression and extent by reducing cartilage degradation in our experimental setting. If these results are confirmed by human trials, simvastatin might be considered by orthopedic surgeons as a disease-modifying drug during the early inflammatory phase of posttraumatic OA.

1 September 2016 in Journal of Orthopaedic Science
Verified
Journal Article
Closed access
UKUlunay Kanatlı
Ulunay Kanatlı
EAErdem Aktas
Erdem Aktas
HYHaluk Yetkin
Haluk Yetkin

4 November 2015 in Stem Cell Reviews and Reports
Verified
Journal Article
Closed access
PDF file
ESErin E. Saether
Erin E. Saether
CCConnie S. Chamberlain
Connie S. Chamberlain
EAErdem Aktas
Erdem Aktas
ELEllen M. Leiferman
Ellen M. Leiferman
SBStacey L. Brickson
Stacey L. Brickson
RVRay Vanderby
Ray Vanderby

1 November 2016 in Journal of Shoulder and Elbow Surgery
Verified
Journal Article
Closed access
UKUlunay Kanatli
Ulunay Kanatli
TATacettin Ayanoğlu
Tacettin Ayanoğlu
EAErdem Aktaş
Erdem Aktaş
MAM. Baybars Ataoğlu
M. Baybars Ataoğlu
MÖMustafa Özer
Mustafa Özer
MÇMehmet Çetinkaya
Mehmet Çetinkaya